key: cord-0711438-1s32771z authors: Cuker, Adam; Despotovic, Jenny M.; Grace, Rachael F.; Kruse, Caroline; Lambert, Michele P.; Liebman, Howard A.; Lyons, Roger M.; McCrae, Keith R.; Pullarkat, Vinod; Wasser, Jeffrey S.; Beenhouwer, David; Gibbs, Sarah N.; Yermilov, Irina; Broder, Michael S. title: Tapering thrombopoietin receptor agonists in primary immune thrombocytopenia: Expert consensus based on the RAND/UCLA modified Delphi panel method date: 2020-12-08 journal: Res Pract Thromb Haemost DOI: 10.1002/rth2.12457 sha: 2473210e4320ae4ce41d0a2c52d0118bb37f1610 doc_id: 711438 cord_uid: 1s32771z BACKGROUND: Thrombopoietin receptor agonists (TPO‐RAs) are used to treat primary immune thrombocytopenia (ITP). Some patients have discontinued treatment while maintaining a hemostatic platelet count. OBJECTIVES: To develop expert consensus on when it is appropriate to consider tapering TPO‐RAs in ITP, how to taper patients off therapy, how to monitor patients after discontinuation, and how to restart therapy. METHODS: We used a RAND/UCLA modified Delphi panel method. Ratings were completed independently by each expert before and after a meeting. Second‐round ratings were used to develop the panel’s guidance. The panel was double‐blinded: The sponsor and nonchair experts did not know each other’s identities. RESULTS: Guidance on when it is appropriate to taper TPO‐RAs in children and adults was developed based on patient platelet count, history of bleeding, intensification of treatment, trauma risk, and use of anticoagulants/platelet inhibitors. For example, it is appropriate to taper TPO‐RAs in patients who have normal/above‐normal platelet counts, have no history of major bleeding, and have not required an intensification of treatment in the past 6 months; it is inappropriate to taper TPO‐RAs in patients with low platelet counts. Duration of ITP, months on TPO‐RA, or timing of platelet response to TPO‐RA did not have an impact on the panel’s guidance on appropriateness to taper. Guidance on how to taper patients off therapy, how to monitor patients after discontinuation, and how to restart therapy is also provided. CONCLUSION: This guidance could support clinical decision making and the development of clinical trials that prospectively test the safety of tapering TPO‐RAs. • Thrombopoietin receptor agonists (TPO-RAs) are used to treat immune thrombocytopenia (ITP). • Some patients with ITP have discontinued TPO-RAs and still maintain a hemostatic platelet count. • Using a modified Delphi panel method, we developed expert consensus on tapering TPO-RAs. • This guidance can support patient care and inform clinical trials on tapering TPO-RAs. Primary immune thrombocytopenia (ITP) is an acquired disorder that affects 2-5 per 100 000 people and is characterized by an increased risk of bleeding, fatigue, and reduced quality of life. 1,2 ITP results from immune-mediated platelet destruction and impaired platelet production. 3 The primary goal of ITP therapy is to reduce the risk of clinically significant bleeding. 4 Glucocorticoids, with or without intravenous immune globulin, are typically used as first-line therapy but are not recommended for long-term use. Second-line therapies include splenectomy, rituximab, and thrombopoietin receptor agonists (TPO-RAs), such as romiplostim, eltrombopag, and avatrombopag. 4 TPO-RAs are used to stimulate platelet production. In initial clinical trials, platelet counts returned to pretreatment levels within approximately 2 weeks of discontinuing TPO-RAs. 5, 6 However, some retrospective and prospective cohort studies have shown that 3%-33% of patients with ITP, including those treated early in their ITP course, may go into remission and maintain hemostatic platelet counts after tapering and discontinuing TPO-RAs (although studies differed in their definition of remission and follow-up duration). [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] Most of these cohort studies were not designed to assess the feasibility of TPO-RA discontinuation. The true prevalence of patients able to maintain a hemostatic platelet count off therapy is unknown, and while a gradual tapering to discontinuation has been advised to avoid rebound thrombocytopenia, 18, 19 factors associated with successful discontinuation have not been identified. Large randomized clinical trials on the management of ITP, including when and how to safely taper or discontinue TPO-RAs, are lacking. As a result, current clinical practice guidelines do not include recommendations on the most appropriate patients for whom tapering may be considered, nor when and how to safely taper TPO-RAs. 4, 20 In these circumstances, guidance based on expert opinion and clinical experience can be helpful in exploring factors that might be associated with successful TPO-RA discontinuation to support clinical care, avoid unnecessary treatment and potential side effects, decrease cost, and inform future clinical trials. Zaja et al 21 Cooper et al 22 took a similar approach and conducted surveys of international experts to explore these factors. We conducted a study using a standardized method of soliciting expert opinion to develop consensus from experts in the United States on when it is appropriate to consider tapering TPO-RAs in children and adults with persistent or chronic primary ITP, how to taper patients off therapy, how to monitor patients after discontinuation, and how to restart therapy in the event of relapse. We used the RAND/UCLA modified Delphi panel method, which is fully described elsewhere. [23] [24] [25] Briefly, this method is a formal group judgment process which systematically and quantitatively combines expert opinion and systematic literature review evidence by asking panelists to rate, discuss, and then rerate various patient scenarios. The primary steps in the process include identification of the question to be answered, a systematic literature review of the evidence, selection of expert panelists, generation of a rating form, first-round survey, a meeting in which panelists discuss areas of disagreement, final ratings and analysis of those ratings, and development of a written summary of areas of agreement and disagreement. A visual representation of this process is provided in Figure 1 . Our expert panel included nine hematologists (six adult hematologists, three pediatric hematologists) with extensive experience treating ITP and one patient representative. The hematologists were from a variety of practice settings (six academic, three community/ private practice) and US regions (four Northeast, one Midwest, two South, two West) with an average of 25 years of experience. The panel was double-blinded while work was ongoing: The sponsor (Novartis) did not know the identity of the nonchair experts, and the nonchair experts did not know the identity of the sponsor until a manuscript of the work was drafted and funding sources were disclosed. Nonchair experts received honoraria for their participation. One expert served as the panel chair and was not blinded to the sponsor and did not receive an honorarium. The sponsor did not provide input on study design, methods, results, or interpretation of findings. No human subjects were involved in this research; thus, ethics committee approval was not required. We collaboratively developed the rating form through individual telephone interviews with panelists. We began by developing a list of patient characteristics that might affect a clinician's decision to discontinue TPO-RA monotherapy in adults and children. Over several conversations, we added to, clarified, removed, and grouped those characteristics. In brief, we assembled clinical experts, conducted a literature review of the evidence, developed a rating form (survey), completed the rating form before a meeting, discussed our ratings at a 6-hour virtual meeting, completed the rating form a second time following the meeting, analyzed these second-round ratings, and developed a written summary of areas of agreement and disagreement patient because the risks of discontinuing treatment outweigh the benefits") and 9 = appropriate ("I would recommend tapering treatment in this patient because the benefits of discontinuing treatment outweigh the risks"). We also defined the setting for these scenarios: we assumed the patient was any age, on TPO-RA monotherapy for some period of time for the treatment of persistent or chronic ITP, was having a successful treatment response (defined as a platelet count ≥30 × 10 9 /L and at least doubling of the baseline 4 ), and was asymptomatic or only had symptoms of petechiae and/or bruising. We also assumed the provider accounted for patient preference, the patient agreed with the provider's decision on whether to taper, and the patient would be reasonably compliant with the care plan. While there may be a variety of reasons to taper patients off TPO-RAs (eg, bridge therapy to splenectomy or rituximab, adverse effects, lack of treatment response, no longer able to afford treatment), we chose not to focus on these scenarios. In addition, we discussed how to taper patients off TPO-RA monotherapy, how to monitor patients after discontinuing TPO-RAs, and how to restart TPO-RAs in the event of relapse. In the final rating form, we included all the different ways that panelists reported tapering TPO-RAs (12 items), monitoring patients after discontinuation (11 items), and restarting therapy (5 items). We rated how appropriate each item is for patient care using a scale of 1 to 9, where 1 = inappropriate ("This action represents a significant problem with quality of care") and 9 = appropriate ("This action represents the best quality of care"). Ratings were completed independently by each expert before the panel meeting (first-round ratings). While we had originally planned to hold the meeting in person, we ultimately met using a virtual platform due to the COVID-19 pandemic. At the virtual meeting, we discussed the scenarios and items on which there was disagreement (defined below). Ratings were completed a second time at the conclusion of the meeting (second-round ratings). Median ratings were calculated for each item using Microsoft Excel. As is typical in the RAND/UCLA modified Delphi panel method, we defined items with disagreement as single items that had two or Current platelet count TA B L E 1 (Continued) more ratings between 1 and 3 and two or more ratings between 7 and 9. 25 Items without disagreement were grouped into three categories based on their median (1 to <4, ≥4 to <7, ≥7 to 9). Using the second-round ratings, we identified patient characteristics on which there was agreement that it was inappropriate (ratings 1 to <4 without disagreement) or appropriate (ratings ≥ 7 to 9 without disagreement) to taper TPO-RA monotherapy. We also conducted chisquared tests using SAS version 9.4 (SAS Institute, Cary, NC, USA) to determine which characteristics had a statistically significant impact on ratings (defined as P < .05). In addition, we identified actions the panel agreed would be inappropriate (ratings 1 to <4 without disagreement) or appropriate (ratings ≥ 7 to 9 without disagreement) to take to taper TPO-RA monotherapy, monitor patients after discontinuation, and restart therapy in the event of relapse. The proportion of items with disagreement decreased from 20% to 10% following the panel meeting. Every clinical situation is different, with its own set of complex characteristics. The consensus statements presented here are in no way intended to supersede clinician decision making and are intended only as general guidance. In developing this guidance, the panel assumed the patient was on TPO-RA monotherapy for treatment of persistent or chronic ITP for some period of time, was involved in the decision-making process, was having a successful treatment response (defined as a platelet count ≥30 × 10 9 /L and at least doubling of baseline), 4 and was asymptomatic or only had symptoms of petechiae and/or bruising, and would be reasonably compliant with the care plan. The panel identified circumstances when it is inappropriate or appropriate to consider tapering (with the aim of discontinuing) TPO-RA monotherapy (illustrated in Table 4 and Figure 2 ). It is usually inappropriate to consider tapering TPO-RA monotherapy in the following circumstances: • In patients with low platelet counts (30-50 × 10 9 /L). • In patients with less than normal but still adequate platelet counts (50-150 × 10 9 /L) who have a history of major bleeding. • In patients with less than normal but still adequate platelet counts (50-150 × 10 9 /L) who have required an intensification of treatment between 3 and 6 months ago and are using anticoagulants or platelet inhibitors. • In patients who, regardless of platelet count, have a high risk of trauma and are using anticoagulants or platelet inhibitors. Assuming that there are no contraindications as outlined above, the panel determined that it is usually appropriate to consider tapering TPO-RA monotherapy in the following circumstances: • In patients with normal or above normal platelet counts (>150 × 10 9 /L), no history of major bleeding, and who have not required an intensification of treatment in the past 6 months. • In patients with normal or above-normal platelet counts (>150 × 10 9 /L), no history of major bleeding, and have required an intensification of treatment between 3 and 6 months ago, as long as they have a low risk of trauma and are not using anticoagulants or platelet inhibitors. • In patients with normal or above-normal platelet counts (>150 × 10 9 /L) who have a history of major bleeding, as long as they have a low risk of trauma, are not using anticoagulants or platelet inhibitors, and have not required an intensification of treatment in the past 6 months. • In a subset of patients with a less-than-normal but still adequate platelet count (50-150 × 10 9 /L), as long as they have no history of bleeding, have not required an intensification of treatment in the past 6 months, have a low risk of trauma, and are not using anticoagulants or platelet inhibitors. The circumstances the panel identified as "appropriate" to consider tapering therapy do not mean that therapy must or should be tapered, but rather that tapering could be an acceptable option. There were areas of remaining uncertainty, either because the panel members disagreed about whether tapering should begin in those circumstances (with some experts feeling it was inappropriate and others that it was appropriate) or because the entire panel was uncertain about those circumstances. These areas are illustrated in white in Table 4 . The panel agreed it is inappropriate to discontinue TPO-RA mon- ], holds an occupation associated with high risk of trauma, has a high fall risk, high-energy toddlers). l For treatment of comorbidity (eg, aspirin, clopidogrel, nonsteroidal anti-inflammatory drugs, heparin, warfarin, direct oral anticoagulants). A patient with no history of bleeding*, is having a successful treatment response, and is currently asymptomatic (or has no or mild bleeding † ): When there is heterogeneity within a scenario, do your best to answer each question for a typical patient with those characteristics. The panel also agreed that it is appropriate to measure the platelet count soon after the patient has discontinued treatment (eg, within 1 to 2 weeks) and with decreasing frequency over time assuming a successful taper. However, we did not reach consensus on a specific schedule for platelet count monitoring over time. The panel also noted that it may be appropriate to measure the platelet count during viral illness and/or vaccine administration; at signs of new bleeding symptoms; before a scheduled invasive procedure; and if the patient is started on therapy that affects bleeding risk (eg, anticoagulants, platelet inhibitors). It is appropriate to ask patients during clinical visits about signs of bleeding and fatigue. Median ≥7-9 without disagreement, % (n) Percentages may not add to 100 due to rounding. a ≥2 ratings of 1-3 and ≥2 ratings of 7-9. b Chi-square tests were conducted to determine whether distribution of ratings differed significantly by characteristic. c Refer to Table 1 for definitions of characteristics. The panel agreed that, in many cases, it is appropriate to consider restarting therapy when the patient's platelet count is <30 × 10 9 /L and shows any signs of bleeding beyond skin manifestations. However, the panel acknowledged that thresholds for restarting therapy may be different for patients with different characteristics. When resumption of TPO-RA therapy is warranted, we agreed that it may be appropriate to restart the TPO-RA at the baseline dose (the dose of TPO-RA the patient was on when the decision to start the taper was made). We used a validated methodology to develop the first set of consensus statements from US clinical experts on tapering TPO-RA monotherapy in patients with persistent or chronic primary ITP. While it was previously thought that patients with ITP would have to remain on TPO-RAs indefinitely to maintain adequate platelet counts, recent case reports and cohort studies have shown that selected patients with ITP can safely discontinue treatment. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] However, to date, no formal guidelines identify which patients can successfully discontinue TPO-RAs. 4, 20 In response to this need, we developed consensus statements on when it is appropriate to consider tapering TPO-RAs; broad guidance on how to taper patients off therapy, how to monitor patients after discontinuation, and how to restart therapy in the event of relapse is also provided. Without large randomized controlled trials, expert opinion can be helpful in exploring patient characteristics and other factors that might be associated with successful TPO-RA discontinuation. We hope this guidance is useful to support patient care. However, as noted earlier, these consensus statements are not intended to supersede clinical judgment or shared clinical decision making. We recognize that these consensus statements reflect the opinion of a small group of individuals. Nevertheless, a validated method was used to develop these statements. The RAND/UCLA modified Delphi panel method has been used extensively to develop quality measures and guidance in a variety of clinical areas, 40 and there is evidence that the resultant measures have content, construct, and predictive validity. 41 In addition, the method has been shown to produce guidance statements that improve health outcomes. [42] [43] [44] The half-lives than romiplostim, which is administered subcutaneously weekly. [45] [46] [47] The panel also included guidance for consideration to restart the TPO-RA if the platelet count drops below 30 × 10 9 /L. Our study has several limitations. First, we did not use randomized controlled trial results to develop our guidance because such evidence on the discontinuation of TPO-RAs does not exist; TA B L E 4 Circumstances when it is inappropriate or appropriate to consider tapering TPO-RA monotherapyAQ10 F I G U R E 2 Patient flowchart of circumstances when it is inappropriate or appropriate to consider tapering TPO-RA monotherapy. This figure represents circumstances when experts agreed it is inappropriate (red boxes), appropriate (green boxes), or were uncertain (gray boxes) whether to consider tapering (with the aim of discontinuing) TPO-RA monotherapy. To read this flowchart, start by determining the patient's current platelet count and follow the arrows based on other patient characteristics. * Current platelet count on treatment (within 2 weeks) is responding but still low (eg, 30-50 × 10 9 /L). † Current platelet count on treatment (within 2 weeks) is adequate for a patient with ITP (eg, 50-150 × 10 9 /L). ‡ Current platelet count on treatment (within 2 weeks) is normal/above normal for a patient without ITP (eg, >150 × 10 9 /L). § Bleeding defined as World Health Organization grade 3 or 4, Buchanan severe grade, Bolton-Maggs and Moon "major bleeding," ITP Bleeding Scale grade 2 or higher, life-threatening or intracerebral. ¶ Any bleeding (other than skin manifestations) not meeting the criteria for "major bleeding." ** No bleeding other than skin manifestations (eg, minimal bruising or scattered petechiae The incidence of idiopathic thrombocytopenic purpura among adults: a population-based study and literature review The incidence of immune thrombocytopenic purpura in children and adults: a critical review of published reports Immune thrombocytopenia American Society of Hematology 2019 guidelines for immune thrombocytopenia Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study Sustained remissions of immune thrombocytopenia associated with the use of thrombopoietin receptor agonists: sustained ITP remissions after TPO receptor agonists The temporary use of thrombopoietin-receptor agonists may induce a prolonged remission in adult chronic immune thrombocytopenia. Results of a French observational study Sustained responses following treatment with romiplostim in immune thrombocytopenia: a single-centre experience Efficacy and safety of eltrombopag in adult refractory immune thrombocytopenia Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia: discontinuation of eltrombopag in primary ITP Feasibility of romiplostim discontinuation in adult thrombopoietin-receptor agonist responsive patients with primary immune thrombocytopenia: an observational retrospective report in real life clinical practice Sustained remission of chronic immune thrombocytopenia after discontinuation of treatment with thrombopoietin-receptor agonists in adults Changes in bone marrow morphology in adults receiving romiplostim for the treatment of thrombocytopenia associated with primary immune thrombocytopenia Efficacy and safety of eltrombopag in treatment-refractory primary immune thrombocytopenia: a retrospective study Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study Remissions after long-term use of romiplostim for immune thrombocytopenia Assessment of a therapeutic strategy for adults with severe autoimmune thrombocytopenic purpura based on a bleeding score rather than platelet count Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working Group Updated international consensus report on the investigation and management of primary immune thrombocytopenia Tapering and discontinuation of thrombopoietin receptor agonists in immune thrombocytopenia: real-world recommendations Tapering and Discontinuation of Thrombopoietin Receptor Agonists in ITP: Consensus Summary of Expert Opinions Consensus methods: characteristics and guidelines for use Research methods used in developing and applying quality indicators in primary care The Rand/UCLA appropriateness method user's manual Repeated short-term use of eltrombopag in patients with chronic immune thrombocytopenia (ITP) Romiplostim as early treatment for refractory primary immune thrombocytopenia Oral eltrombopag for up to three years is safe and well-tolerated in Japanese patients with previously treated chronic immune thrombocytopenia: an open-label, extension study Successful treatment with eltrombopag in avoiding splenectomy for patients with chronic refractory immune thrombocytopenia Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program Sustained remission in patients with primary immune thrombocytopenia after romiplostim tapering and discontinuation: a case series in real life management in Spain Prolonged remission from eltrombopag in chronic refractory idiopathic thrombocytopenic purpura Spontaneous remission after a year of romiplostim in an adult patient with refractory primary immune thrombocytopenia Repeated successful use of eltrombopag in chronic primary immune thrombocytopenia: description of an intriguing case Complete remission of refractory immune thrombocytopenia (ITP) with a short course of romiplostim Total remission of severe immune thrombocytopenia after short term treatment with romiplostim Successful discontinuation of eltrombopag in one child with refractory primary immune thrombocytopenia and literature review Case study of remission in adults with immune thrombocytopenia following cessation of treatment with the thrombopoietin mimetic romiplostim Romiplostim in adult patients with newly diagnosed or persistent immune thrombocytopenia ( ITP ) for up to 1 year and in those with chronic ITP for more than 1 year: a subgroup analysis of integrated data from completed romiplostim studies Using and reporting the Delphi method for selecting healthcare quality indicators: a systematic review Validity of criteria used for detecting underuse of coronary revascularization Underuse of coronary revascularization procedures in patients considered appropriate candidates for revascularization Appropriate use criteria for coronary revascularization focused update: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery Validation of the appropriate use criteria for percutaneous coronary intervention in patients with stable coronary artery disease (from the COURAGE trial) Avatrombopag for the treatment of immune thrombocytopenia The reproducibility of a method to identify the overuse and underuse of medical procedures Thrombopoietin receptor agonist use in children: data from the Pediatric ITP Consortium of North America ICON2 study: thrombopoietin receptor agonist use in children Boston Children's Cancer and Blood Disorders Center Tapering thrombopoietin receptor agonists in primary immune thrombocytopenia: Expert consensus based on the RAND/UCLA modified Delphi panel method All authors critically reviewed and approved the content. https://orcid.org/0000-0002-1215-642X